A number of pharmacological agents for treating negative symptoms in schizophrenia are currently in development. Unresolved questions regarding the design of clinical trials in this area were discussed at an international meeting in Florence, Italy in April 2012. Participants included representatives from academia, the pharmaceutical industry, and the European Medicines Agency (EMA).

Marder SR, Alphs L, Anghelescu I, Arango C, Barnes TRE, Caers I, Daniel D, Duneyevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn R, Kane JM, Keefe RSE, Kinon B, Leucht S, Lindenmayer JP, Malhotra A, Stauffer V, Umbricht D, Wesnes K, Kapur S, Rabinowitz J. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.  Schizophrenia Bulletin, Schizophrenia Research, 2013; 150(2): 328-333.